Objective: To analyze whether KCNQ2 R201C and R201H variants, which show atypical gain-of-function electrophysiologic properties in vitro, have a distinct clinical presentation and outcome. Methods: Ten children with heterozygous, de novo KCNQ2 R201C or R201H variants were identified worldwide, using an institutional review board (IRB)-approved KCNQ2 patient registry and database. We reviewed medical records and, where possible, interviewed parents and treating physicians using a structured, detailed phenotype inventory focusing on the neonatal presentation and subsequent course. Results: Nine patients had encephalopathy from birth and presented with prominent startle-like myoclonus, which could be triggered by sound or touch. In seven patients, electroencephalography (EEG) was performed in the neonatal period and showed a burst-suppression pattern. However, myoclonus did not have an EEG correlate. In many patients the paroxysmal movements were misdiagnosed as seizures. Seven patients developed epileptic spasms in infancy. In all patients, EEG showed a slow background and multifocal epileptiform discharges later in life. Other prominent features included respiratory dysfunction (perinatal respiratory failure and/or chronic hypoventilation), hypomyelination, reduced brain volume, and profound developmental delay. One patient had a later onset, and sequencing indicated that a low abundance (~20%) R201C variant had arisen by postzygotic mosaicism. Significance: Heterozygous KCNQ2 R201C and R201H gain-of-function variants present with profound neonatal encephalopathy in the absence of neonatal seizures. Neonates present with nonepileptic myoclonus that is often misdiagnosed and treated as
• Children have a neonatal encephalopathy with nonepileptic myoclonic jerks, central hypoventilation, and profound developmental delay with early mortality
• In vitro functional studies in KCNQ2 translate to in vivo clinical entities, supporting the use of distinct targeted treatments for specific patient subgroups Pathogenic variants in KCNQ2, a gene well-known to be involved in benign familial neonatal epilepsy (BFNE), have emerged as an important cause of neonatal-onset epileptic encephalopathy (KCNQ2 encephalopathy). [1] [2] [3] [4] [5] BFNE is characterized by seizure onset within the first days of life, seizure remission within months, normal interictal electroencephalography (EEG), and normal development, but increased postneonatal seizure risk. 2, 6 Patients with KCNQ2 encephalopathy also present with frequent neonatal seizures, but their interictal EEG is severely abnormal and characterized by multifocal epileptiform abnormalities with random attenuations or a burst-suppression pattern, and they have moderate to profound developmental delay. 5, 7 BFNE arises from KCNQ2 alleles causing haploinsufficiency (including deletion of the entire gene) and from missense variants that exhibit partial loss-of-function in vitro. [8] [9] [10] Studies of several KCNQ2 variants that cause KCNQ2 encephalopathy reveal more extensive loss-of-function or a dominant negative effect. 11, 12 These studies suggest a potential direct relationship between the degree of loss-offunction and clinical severity. 11, 12 Recently, the KCNQ2 missense variants R201C and R201H 5, 13 were shown to increase channel opening in vitro, a gain-of-function effect opposite to the loss-of-function produced by previous BFNE and KCNQ2 encephalopathy variants. 14 Given the distinctive molecular physiology of KCNQ2 R201C and R201H in vitro, we investigated whether these variants result in a distinct phenotype. We report detailed clinical data on the neonatal presentation of 10 children who were heterozygous for KCNQ2 R201C/H and describe a unique electroclinical phenotype that includes neonatal encephalopathy without seizures, exaggerated startle response that is often misdiagnosed as seizures, burst-suppression EEG pattern at birth with evolution into multifocal epileptiform discharges, early hypoventilation and supplemental oxygen requirement, hypomyelination, and profound developmental delay with early mortality.
Methods
We studied a cohort of patients with de novo KCNQ2 R201C or R201H variants that were included in the Rational Intervention of KCNQ2 Epileptic Encephalopathy (RIKEE) database (http://www.RIKEE.org), a curated database aggregating published information and unpublished patient data provided by physicians or families after parental informed consent. Based on the electroclinical features of a newly diagnosed newborn with a de novo R201C variant (patient A, Table 1 ), a detailed clinical questionnaire was sent to the referring physician of all identified patients, including the one previously published patient with a R201C variant (patient D in current study and patient B in Weckhuysen et al. 5 ). Data requested included information on neonatal neurologic exam, presence of paroxysmal events/seizures or abnormal movements in the neonatal period and later in life, whether seizures were confirmed by EEG, EEG findings in the neonatal period and during follow-up, antiseizure drugs used, neuroimaging findings, other body system involvement, neurodevelopment, and mortality. The actual video-EEG recordings, when available, were reviewed by a neonatal neurophysiologist (MRC). For some patients, members of the investigative team spoke directly with the parent via conference call to better understand the early presentation and course. The respective KCNQ2 variants were identified in different diagnostic or research laboratories, using targeted gene panels that included KCNQ2 or single gene Sanger sequencing. All variants were proven to occur de novo. Parental consent was obtained to include patient videos.
Results

Neurologic presentation
Eight patients with heterozygous de novo R201C variants and two patients with heterozygous de novo R201H variants were identified (Table 1 ). The majority of infants were born at term after uncomplicated gestations and deliveries. Patient C had bradycardia prior to delivery via caesarian section. One child (patient H) was found to carry a postzygotic mosaic variant; this patient had later symptom onset and is discussed below. The remaining nine patients presented with encephalopathy at birth (milder in the R201H cases) and developed prominent, abnormal body movements within the first 2 days of age. The movements were characterized by highamplitude spontaneous myoclonic jerks that were triggered by touch and sound, suggesting an exaggerated startle response (Video S1). These paroxysmal movements were clinically considered as epileptic seizures in eight patients and treated with antiseizure medications without success. However, where available for review (patients A, D, and G), neonatal video-EEG studies demonstrated that the abnormal paroxysmal movements lacked EEG correlates and were consistent nonepileptic myoclonus.
EEG was performed in the neonatal period in seven infants, and in all of them it demonstrated an invariant burst-suppression pattern (Fig. 1A) . Neurologic examination was notable for diffuse hypotonia and marked hyperreflexia in eight patients. Brain magnetic resonance imaging (MRI) in five patients was obtained at ≤10 days of age, and was reported as normal (n = 2) or showed mild reduced brain volume (n = 3).
After 1 month of age, the EEG showed a pattern of multifocal epileptiform discharges in all 10 infants (Fig. 1B) . Seven infants developed epileptic spasms at a median age of 5 months (range 3-24 months). All four infants who had neonatal EEG and developed epileptic spasms showed a burst-suppression pattern in the neonatal period. Brain MRI was obtained in eight infants between one and 24 months of age and revealed hypomyelination and reduced brain volume in six patients (Fig. 2) and abnormal signal in the basal ganglia in one patient (F). Reduced brain volume became more evident on follow-up brain MRI. Patient A also had subependymal heterotopias (Fig. 2) . The patients had profound developmental delay without the achievement of discernable developmental motor milestones and were nonverbal. One patient (I) later in life (Video 2) developed severe choreoathetosis; however, it is possible that similar movement disorders, including choreoathetosis and myoclonus-dystonia, occurred in some of the other patients. Four patients had early mortality ranging from 4.5 months to 6.3 years. The other six children are alive and currently between 19 months and 5 years of age.
One patient (H) did not have encephalopathy or paroxysmal events as a newborn. She was noted to have only mild axial hypotonia, and by age 1 year could sit, crawl in a supine position, and roll over independently; although she showed some developmental delay, she could reach milestones not attained by the other nine patients. However, in the second year of life, developmental regression occurred The difference between the observed frequency and 50% (expected for heterozygosity) was highly significant (p = 3.6 9 10 À8 , Binomial exact test). 15 Consistent with whole exome sequencing results, when bidirectional Sanger sequencing was performed in parallel on the trio, the variant peak was estimated as 15-25% of the total at base 601.
Treatment
All patients were trialed on multiple medications (Table 1) . Given the genetic mutation in KCNQ2, five patients were trialed on retigabine/ezogabine (European name/U.S. name) between 17 days and 4 years of age with little or no response. Patient A was slowly escalated to a dose of 7 mg/kg every 8 h over a period of 3 weeks to a level of 1,600 ng/mL. While the patient was on ezogabine, the EEG continued to have a pattern of severe encephalopathy and there was no clinical improvement in respiratory or neurologic status. Gamma-glutamyl transferase became elevated to 404 U/L, although aspartate aminotransferase and alanine aminotransferase remained normal. Given the lack of response, ezogabine was discontinued. Patient G had clinical worsening on retigabine at 6 months of age with increased paroxysmal events, prolonged apneas, and severe sedation. Patient E had subjective improvement with increased wakefulness when on retigabine at 4 years of age. Three patients with epileptic spasms were treated with hormonal therapy (adrenocorticotropic hormone) with poor response (patients F, H, and J). In two of these patients, spasms reduced, although they did not resolve, after starting vigabatrin. All 10 infants were treated with vigabatrin early in life. In five patients, a noticeable reduction in either the exaggerated startle/myoclonic jerks (patients A and C) or a reduction in spasms (patients F, G, and H) was noted. Of interest, patient A was treated with vigabatrin for control of exaggerated startle and jerking at 4 months of age and did not develop epileptic spasms.
Other system involvement Respiratory problems, including respiratory failure and recurrent aspiration pneumonia, were common among these patients (Table 1 ). In six patients (A-D, F, and G) there was respiratory failure and hypoventilation at birth, and mechanical ventilation or oxygen supplementation was required. Patient A required invasive mechanical ventilation until 2 weeks of age and then required noninvasive positive pressure ventilation until 2 months of age due to hypoventilation and chronically elevated pCO 2 , unresponsive to caffeine, theophylline, and aminophylline treatments. After discontinuation of mechanical ventilation, patient A exhibited excessive sighing and atypical periodic breathing associated with intermittent hypoxia (Fig. 3) . Congenital central hypoventilation syndrome (CCHS) was considered, although patients with CCHS usually have normal EEG findings. However, Sanger sequencing revealed no variants in PHOX2b, and whole exome sequencing did not reveal a mutation in other genes linked to CCHS. 16 Chronic compensated respiratory acidosis with an irregular breathing pattern was seen in patient G, who received supplemental oxygen until 6 months of age. Patient D also had chronically elevated pCO 2 , received supplemental oxygen, and died suddenly, overnight, without preceding infection. Patients E, I, and J had recurrent aspiration pneumonias and often required admission to the intensive care unit for respiratory insufficiency. Patient J had clubbing of the finger nails at 5 years of age.
Three patients developed diabetes insipidus (A, C, and F) between 1 and 2 months of age that in patient A required prolonged Desmopressin treatment and did not self-resolve. The only dysmorphic feature documented in the infants was an abnormal palate; Patient D had a cleft soft palate, patient G had a cleft palate, and patient C had a high-arched palate. All patients were fed by gastrostomy tube.
Discussion
Patients with the gain-of-function KCNQ2 R201C and R201H variants have a severe form of KCNQ2 encephalopathy with a phenotype that is novel and distinct from what has been reported for other KCNQ2 encephalopathy variants. Previously undescribed features include neonatal encephalopathy without seizures, exaggerated and prolonged startle response with bilateral high amplitude myoclonic jerks The position of the variant likely has an impact on the clinical expression. Although BFNE-associated variants are distributed randomly throughout the channel protein and include missense, splice, stop, and frameshift variants as well as exon and whole-gene deletions, currently known KCNQ2 encephalopathy variants are missense or single-codon deletions, clustering in four functionally important protein domains: the voltage sensor domain, the pore, the C-terminus proximal region, and the calmodulin-binding B helix region. 17 Within the voltage sensor domain, most KCNQ2 variants causing encephalopathy reduce channel function (often with dominant-negative effects). 11, 12 However, a few variants at residues directly involved in voltage sensor domain resting state stabilization (i.e., to date, R144Q, V175L, R201C, R201H, and R198Q) produce gain-of-function effects by shifting activation to more hyperpolarized potentials and/or increasing maximal current density. 14, 18, 19 Both de novo loss-of-function and the R201C/H gain-offunction variants lead to a neonatal encephalopathy characterized by a burst-suppression EEG pattern. However, even though 70% of the patients in our series developed epileptic spasms in infancy, the absence of seizures in the neonatal period seems to be a peculiarity of the gain-of-function variants. In fact, no neonatal seizures or encephalopathy were reported in four patients carrying a milder KCNQ2 R198Q gain-of-function variant who later developed epileptic spasms at 4-6 months of age. 19 Excessive startle response as a prominent neonatal feature was observed for the R201C/H gain-of-function variants. The paroxysmal movements were described as myoclonic in many of the cases. Myoclonic jerks associated with encephalopathy and a burst-suppression EEG pattern are seen in neonates with early myoclonic encephalopathy (EME). However, in EME, myoclonus is typically fragmentary, erratic, of low amplitude, tends to shift from one body part to another in a random asynchronous fashion, and is not induced by a stimulus. 20 In our patients, the myoclonic movements were massive, elicited by tactile or acoustic stimuli, tended to persist after the end of the stimulus, and were difficult to distinguish from epileptic movements without simultaneous video-EEG recording. They were indeed clinically diagnosed as seizures and treated as such in most cases of our series. Such a misdiagnosis is not surprising, since it is often impossible to accurately differentiate between seizures and nonepileptic paroxysmal movements in neonates using clinical evaluation alone. 21 Semiologically, the exaggerated startle response is reminiscent of hyperekplexia, a genetic condition due to mutations affecting spinal glycine neurotransmission that is characterized by an exaggerated startle response to stimuli, with a brief period of stiffness following the startle reflex. 22 However, EEG in hyperekplexia is normal and there is no encephalopathy. 22, 23 The movements of R201C/H neonates are different from the myokymia that affects older patients, with some specific loss-of-function KCNQ2 variants. 24, 25 Such myokymia is rhythmic, and is a sign of lower motor neuron hyperexcitability.
One patient harboring the R201C variant had a less severe phenotype and lacked the early neonatal features that were consistently seen among the other nine patients. Her genetic testing indicated postzygotic mosaicism, which was previously shown to underlie milder presentation of KCNQ2 encephalopathy loss-of-function variants.
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Figure 3.
Respiratory and SpO 2 recording in infant with KCNQ2 R201C variant. Respiratory and pulse oximetry recording at 3 months of age showing excessive sighing and unusual periodic breathing associated with intermittent hypoxia (patient A). Epilepsia ILAE Synchronized activity during prenatal and postnatal periods is essential for the development of cortical neuronal circuits. 27 Our findings suggest that the R201C gain-offunction may disrupt network activity in the neonatal period, but (unlike loss-of-function variants) somehow prevents some aspects of synchronization and/or excitability required for expression of seizures. KCNQ2 channels are also found in neurons of the dorsal root ganglia and nociceptive afferent terminals, where they play a role in pain sensation. [28] [29] [30] Because the paroxysmal movements in our patients were triggered by tactile stimulation, it could be hypothesized that the exaggerated startle response may be secondary to an abnormal sensation to touch.
Early central hypoventilation and abnormal breathing patterns are additional prominent clinical features observed in patients with KCNQ2 R201C/H variants. Apneic episodes and respiratory failure along with neonatal encephalopathy and severe hypotonia have been described in males with methyl-CpG-binding protein 2 (MECP2) mutations, 31 but these infants lack both the distinct paroxysmal movements and severe EEG findings observed in infants with KCNQ2 gain-of-function variants. Apneas are described in loss-offunction variants of KCNQ2 encephalopathy and typically occur as part of a tonic seizure. 5, 32 In our R201C variant patients, however, hypoventilation and apnea observed in the neonatal period were demonstrated to be associated with central hypoventilation rather than seizure activity. Of interest, the KCNQ2 channel has key functions in respiratory drive. 33 Chemosensitive neurons in the retrotrapezoid nucleus of the brainstem are regulated through a pathway that involves serotonergic inhibition of KCNQ2 channels to increase respiratory drive in response to a change in CO 2 / H + . 34 A gain-of-function channel variant by causing excessive channel opening may result in a reduction of respiratory drive due to a decreased sensitivity to inhibition by serotonin despite chronic elevated CO 2 levels. Sulthiame, a carbonic anhydrase inhibitor, given to patient G had a beneficial effect on breathing. KCNQ2 potassium channel subunits have also been detected in branches of the carotid sinus nerve, which provides sensory innervation to the carotid body chemoreceptors, as well as in carotid body glomus cells, which are the main O 2 -sensing cell in the carotid bodies. 35 Little is known about the role of KCNQ2 in the carotid body glomus cells or carotid sinus nerve fibers. Of note, mice homozygous for a KCNQ2 mutation die of respiratory failure after birth. 36 Respiratory problems may contribute to early mortality in KCNQ2 encephalopathy due to R201C/H variants. Animal model and human studies are needed to understand the effect of gain-of-function variants on central and peripheral chemoreflex respiratory control.
In the majority of our patients, MRI showed progressive diffuse brain volume reduction, thin corpus callosum, and hypomyelination. The thinning of the corpus callosum could reflect the bilateral volume loss in the cortex as seen in many other encephalopathies. Brain MRI at 3 months of age in one infant (patient A) showed an additional finding of altered neuronal migration with gray matter heterotopias. Of interest, a neuropathologic report of a neonate with KCNQ2 encephalopathy found mild malformation of cortical development and heterotopic gray matter, 37 and heterotopias were also found in a KCNQ2 transgenic mouse model. 38 The cellular and circuit mechanisms through which altered KCNQ2 channel activity results in such neurodevelopmental structural abnormalities are currently unknown.
Recognition of genotype-phenotype correlations in patients with KCNQ2 variants can have important treatment implications. Retigabine/ezogabine, a KCNQ-channel opener and therefore a presumed targeted therapy for epilepsy involving KCNQ2 loss-of-function, 5, 39 did not improve the myoclonic jerks and the encephalopathy in patients with R201C/H variants and seemed to lead to a worsening of symptoms in one patient (patient G). Given this observation, it is possible that retigabine/ezogabine could exacerbate gain-of-function effects and result in a detrimental clinical effect in some patients. KCNQ2-related epilepsies are therefore a prime example of the need for functional classification of allele subgroups, as gain-of-function and loss-of function require different targeted therapeutic approaches.
The patients with KCNQ2 R201C and R201H variants described in this report define a distinct and very severe form of neonatal encephalopathy and provide a clinical translation of in vitro functional studies. We believe that gain-of-function variants of KCNQ2 should be considered in newborns with unexplained severe encephalopathy, burst-suppression EEG pattern, and stimulus sensitive myoclonic jerks, in the absence of epileptic seizures, as well as in newborns with central hypoventilation. In our series, prognosis was poor. Future investigations should aim at identifying drugs that counteract excessive channel opening as an early targeted therapy that may improve outcome.
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